Investment by Major Companies Propelled Somatostatinoma Treatment Market
Somatostatinoma is an extremely rare pancreatic neuroendocrine tumor (PNET) or duodenal endocrine tumor (DNET), which originates either in the pancreas (50%) or the gastrointestinal tract (50%)
Based on data published in the National Center for Biotechnology Information, an estimated incidence rate of Somatostatinoma is of 1/40,000,000 globally.